Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today noted that our partner, Akeso, Inc. ("Akeso, ...

Background Although voting is recognised as a social determinant of health, the association between electoral participation ...

Advanced MRI radiomics pinpoints aggressive spinal tumour regions to predict outcomes. Learn how this could guide ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

“Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers,” by Dewpoint Therapeutics. News release; Oct. 21, 2025. For more news on cancer ...

Long-acting injectables (LAIs) were designed to solve this problem by reducing the burden of daily pill-taking and ensuring more consistent drug exposure. Underutilization of LAIs in the U.S is common ...

The FDA has approved Kygevvi (doxecitine and doxribtimine) for the treatment of TK2d in adults and pediatric patients with an age of symptom onset on or before 12 years.

Akeso, Inc. (HKEX: 9926.HK) is excited to announce that the final Overall Survival (OS) analysis results from the HARMONi-A study, a Phase III study evaluating ivonescimab combined with chemotherapy ...

Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...

The Istanbul-based Ministry of Health–authorized clinic strengthens its international visibility through verified platforms ...

Altcoin traders use 8-step plan to manage risk, with 72% of top coins down 50%. Here are survival strategies for altcoin ...

Primary OS analysis results from STELLAR-303 showed zanzalintinib + atezolizumab improved OS vs regorafenib in metastatic colorectal cancer.